A Phase I/II clinical trial (NCT00736476) assessed the efficacy of a vaccine composed of vacuolating cytotoxin A (VacA), cytotoxin-associated antigen (CagA), and neutrophil-activating protein (NAP) for preventing infection with cagA-positive strains post-intramuscular immunization. Here, S100A8 is linked to infection.